Prognostic Factors and Survival Outcomes in Thyroid Cancer Patients with Bone Metastasis: Insights from a Population-Based Cohort Study.

IF 3.7 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Endocrine Practice Pub Date : 2025-07-16 DOI:10.1016/j.eprac.2025.07.010

Hang Zhao, Xiaozhun Tang, Duoping Wang, Peng-Cheng Yu, Cong He, Xu-Feng Chen, Wei-Dong Ye, Jia-Hao Wu, Jia-Qian Hu, Yu-Long Wang

{"title":"Prognostic Factors and Survival Outcomes in Thyroid Cancer Patients with Bone Metastasis: Insights from a Population-Based Cohort Study.","authors":"Hang Zhao, Xiaozhun Tang, Duoping Wang, Peng-Cheng Yu, Cong He, Xu-Feng Chen, Wei-Dong Ye, Jia-Hao Wu, Jia-Qian Hu, Yu-Long Wang","doi":"10.1016/j.eprac.2025.07.010","DOIUrl":null,"url":null,"abstract":"Objectives: Thyroid cancer (TC) is the most common endocrine malignancy, and bone metastasis (BM) is the second most common type of metastasis after lung metastasis. BM is associated with a poor prognosis; however, relevant research remains limited. This study aims to evaluate the prognostic factors and survival outcomes in patients with thyroid cancer with bone metastasis (TCBM).Methods: Data from patients with thyroid cancer with bone metastasis were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Univariable and multivariable Cox proportional hazards regression models were used to identify survival predictors. Survival outcomes were calculated using the Kaplan-Meier method and compared using the log-rank tests.Results: A total of 696 TCBM patients from 2010 to 2021 were included in this study. For the TCBM patients, those age ≥55 years (P < 0.001); those with anaplastic thyroid cancer (P < 0.001); those with brain, liver and lung metastases (all P < 0.05); and those with T4 stage disease (P = 0.011) exhibited significantly worse overall survival (OS), with radioisotope therapy (P < 0.001) significantly improved OS. Additionally, significant factors for cancer-specific survival (CSS) included ATC (P < 0.001); liver and lung metastases (all P < 0.001); and radioisotope treatment (P < 0.001).Conclusion: Our study revealed the critical role of age, pathological subtype, metastatic lesions, and radioisotope therapy in determining the prognosis of TCBM. These findings contribute to providing more rational treatment decisions and risk stratification for TCBM patients.","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.eprac.2025.07.010","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Thyroid cancer (TC) is the most common endocrine malignancy, and bone metastasis (BM) is the second most common type of metastasis after lung metastasis. BM is associated with a poor prognosis; however, relevant research remains limited. This study aims to evaluate the prognostic factors and survival outcomes in patients with thyroid cancer with bone metastasis (TCBM).

Methods: Data from patients with thyroid cancer with bone metastasis were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Univariable and multivariable Cox proportional hazards regression models were used to identify survival predictors. Survival outcomes were calculated using the Kaplan-Meier method and compared using the log-rank tests.

Results: A total of 696 TCBM patients from 2010 to 2021 were included in this study. For the TCBM patients, those age ≥55 years (P < 0.001); those with anaplastic thyroid cancer (P < 0.001); those with brain, liver and lung metastases (all P < 0.05); and those with T4 stage disease (P = 0.011) exhibited significantly worse overall survival (OS), with radioisotope therapy (P < 0.001) significantly improved OS. Additionally, significant factors for cancer-specific survival (CSS) included ATC (P < 0.001); liver and lung metastases (all P < 0.001); and radioisotope treatment (P < 0.001).

Conclusion: Our study revealed the critical role of age, pathological subtype, metastatic lesions, and radioisotope therapy in determining the prognosis of TCBM. These findings contribute to providing more rational treatment decisions and risk stratification for TCBM patients.

查看原文本刊更多论文

甲状腺癌骨转移患者的预后因素和生存结果：一项基于人群的队列研究的见解

目的：甲状腺癌（TC）是最常见的内分泌恶性肿瘤，骨转移（BM）是仅次于肺转移的第二常见转移类型。BM与预后不良有关；然而，相关研究仍然有限。本研究旨在探讨甲状腺癌合并骨转移（TCBM）患者的预后因素和生存结局。方法：从监测、流行病学和最终结果（SEER）数据库中提取甲状腺癌合并骨转移患者的数据。使用单变量和多变量Cox比例风险回归模型来确定生存预测因子。使用Kaplan-Meier法计算生存结果，并使用log-rank检验进行比较。结果：2010 - 2021年共纳入696例TCBM患者。对于TCBM患者，年龄≥55岁（P < 0.001）；甲状腺间变性癌患者（P < 0.001）；脑、肝、肺转移者（均P < 0.05）；T4期患者（P = 0.011）总生存期（OS）明显差，放射性同位素治疗（P < 0.001）总生存期明显改善。此外，影响癌症特异性生存（CSS）的重要因素包括ATC (P < 0.001)；肝和肺转移（均P < 0.001）；放射性同位素治疗（P < 0.001）。结论：我们的研究揭示了年龄、病理亚型、转移病灶和放射性同位素治疗在决定TCBM预后中的关键作用。这些发现有助于为TCBM患者提供更合理的治疗决策和风险分层。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Endocrine Practice ENDOCRINOLOGY & METABOLISM-

CiteScore

7.60

自引率

2.40%

发文量

546

审稿时长

41 days

期刊介绍： Endocrine Practice (ISSN: 1530-891X), a peer-reviewed journal published twelve times a year, is the official journal of the American Association of Clinical Endocrinologists (AACE). The primary mission of Endocrine Practice is to enhance the health care of patients with endocrine diseases through continuing education of practicing endocrinologists.